The patient was diagnosed as having cervical brucellar spondylitis with epidural abscess causing incomplete limb paralysis. Quadruple anti-biotherapy had been started with oral doxycycline 200 mg/day ...

Here are five myths about AS that every Black man or woman should know. Myth 1: Kids Don’t Have to Worry A main myth about Ankylosing Spondylitis is that it only affects adults. False. AS can manifest ...

Aim of the study: The aim of this study was to investigate the association of clinical characteristics and treatment of ankylosing spondylitis with the presence of rhythm and conduction disturbances.

Objective Little is known about the prognosis of infections in patients with ankylosing spondylitis (AS) compared with patients without AS. The purpose of this study was to examine whether AS is ...

Léia CR Silva; Luciena CM Ortigosa; Gil Benard Disclosures Immunotherapy. 2010;2 (6):817-833.

Prothena is laying off almost two-thirds of its workforce as the Irish biotech navigates the fallout from giving up on its failed amyloidosis drug. In May, the company announced the failure of the ...

Darzalex as monotherapy was investigated in two main studies involving multiple myeloma patients whose disease relapsed after, or was refractory to, at least two previous treatments, including a ...

Testing for cardiac amyloid burden in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) with SPECT-CT has high reproducibility, according to a study published in the Journal of ...

Join ACC's Cardiovascular Imaging Member Section on Tuesday, Aug. 5 at 5:30 p.m. ET for a case-based, multi-modality webinar of the contemporary cardiovascular imaging evaluation of cardiac ...

The current multi-center Phase 3 trial (NCT05184088) aims to further validate florbetaben (18F)'s efficacy in the diagnosis of cardiac amyloidosis, including the ATTR subtype.

Ankylosing spondylitis flares are no doubt agonizing. The burning pain in your neck and back when those flares erupt can take a heavy emotional and physical toll on you. But you can ease spondylitis ...

CAMBRIDGE, Mass., June 09, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has ...